<DOC>
	<DOCNO>NCT02738853</DOCNO>
	<brief_summary>The study objective evaluate safety efficacy Medtronic TAVR 2.0 system patient severe symptomatic aortic stenosis consider high extreme risk surgical aortic valve replacement</brief_summary>
	<brief_title>The Medtronic TAVR 2.0 US Clinical Study</brief_title>
	<detailed_description>Prospective , single arm , multi-site study . Patients see pre post procedure , discharge , 30 day , 6 month , 1 year , annually 5 year .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic stenosis , define aortic valve area &lt; 1.0 cm2 ( aortic valve area index &lt; 0.6 cm2/m2 ) continuity equation , AND mean gradient &gt; 40 mmHg OR maximal aortic valve velocity &gt; 4.0 m/sec rest echocardiogram 2 . STS score ≥8 OR document heart team agreement ≥ high risk AVR due frailty comorbidities 3 . Symptoms aortic stenosis AND NYHA Functional Class II great 4 . The subject treating physician agree subject return require post procedure followup visit . 1 . Any condition consider contraindication placement bioprosthetic valve ( eg , subject indicate mechanical prosthetic valve ) 2 . A known hypersensitivity contraindication follow adequately pre medicate : aspirin heparin ( HIT/HITTS ) bivalirudin ticlopidine clopidogrel nitinol ( titanium nickel ) contrast medium 3 . Blood dyscrasia define : leukopenia ( WBC &lt; 1000 mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy , hypercoagulable state 4 . Untreated clinically significant coronary artery disease require revascularization 5 . Severe leave ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % echocardiography , contrast ventriculography , radionuclide ventriculography 6 . End stage renal disease require chronic dialysis creatinine clearance &lt; 20 cc/min . 7 . Ongoing sepsis , include active endocarditis 8 . Any percutaneous coronary peripheral interventional procedure bare metal drug elute stent perform within 30 day prior study procedure 9 . Symptomatic carotid vertebral artery disease successful treatment carotid stenosis within 10 week Heart Team assessment 10 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support 11 . Recent ( within 6 month Heart Team assessment ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) 12 . Gastrointestinal ( GI ) bleed would preclude anticoagulation 13 . Subject refuse blood transfusion 14 . Severe dementia ( result either inability provide inform consent study/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) 15 . Estimated life expectancy le 12 month due associate noncardiac comorbid condition 16 . Other medical , social , psychological condition opinion investigator precludes subject appropriate consent adherence protocol require followup exam 17 . Currently participate investigational drug another device study ( exclude registry ) 18 . Evidence acute myocardial infarction ≤30 day study procedure 19 . Need emergency surgery reason 20 . Liver failure ( ChildPugh class C ) 21 . Subject pregnant breast feed 22 . Pre exist prosthetic heart valve position 23 . Mixed aortic valve disease ( aortic stenosis severe aortic regurgitation ) 24 . Severe mitral regurgitation 25 . Severe tricuspid regurgitation 26 . Moderate severe mitral stenosis 27 . Hypertrophic obstructive cardiomyopathy 28 . Echocardiographic MultiSlice Computed Tomography ( MSCT ) evidence intracardiac mass , thrombus , vegetation 29 . Congenital bicuspid unicuspid valve verify echocardiography 30 . Access vessel diameter &lt; 5.5 mm &lt; 6.0 mm patent LIMA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>